|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ӲƤ��,ϵͳ�� |
|
���� |
| ��������������� | |
|
��ϼ |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
ϵͳ��ӲƤ�����Ƶ��о���չ
��ϼ, ����
������ҽ��ѧ��ƺҽԺҰս����о���Ƥ����, ����400042
ӲƤ���ķ������Ʋ���,������һֱ���ٴ������е��ѵ�,Ŀǰ,��ϵͳ��ӲƤ��������Ч�Ʒ�,��Ӧ�õ����Ʒ����϶�,��:Ѫ�����ż����������Ƽ�������ά������һЩ�µ��Ʒ���,����Ч��������,����Ҳ�Ƚ����ѡ����н���ϵͳ��ӲƤ�����Ƶ��о���չ��һ������
[2] Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am, 1996, 22(4):647-674.
[3] Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma:clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum, 1999, 42(12):2646-2655.
[4] Black CM, Halkier-Sorensen L, Belch JJ, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis:a multicentre,placebo-controlled, dose-comparison study. Br J Rheumatol, 1998,37(9):952-960.
[5] Leighton C. Drug treatment of scleroderma. Drugs, 2001, 61 (3):419-427.
[6] Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a threeyear, parallel, randomized, double-blind study. Arthritis Rheum,1989, 32(5):584-593.
[7] van den Hoogen FH, Boerbooms AM, Swaak A J, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis:a 24week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol, 1996, 35(4):364-372.
[8] Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum, 1993, 36(1):75-83.
[9] Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, et al. The impact of pain and symptoms of depression in scleroderma. Pain, 2002,95(3):267-275.
[10] Medsger TA Jr, Lucas M, Wildy KS, et al. D-penicillamine in systemic sclerosis? Yes! Scand J Rheumatol, 2001, 30(4):192-194.
[11] Wigley FM, Sule SD. Novel therapy in the treatment of scleroderma.Expert Opin Investig Drugs, 2001, 10(1):31-48.
[12] Ben-Chetrit E, Levy M. Colchicine:1998 update. Semin Arthritis Rheum, 1998, 28(1):48-59.
[13] Denton CP, Black CM. Novel therapeutic strategies in scleroderma.Curr Rheumatol Rep, 1999, I(1):22-27.
[14] Le CH, Morales A, Trentham DE. Minocycline in early diffuse scleroderma. Lancet, 1998, 352(9142):1755-1756.
[15] Simon JC, Pfieger D, Schopf E. Recent advances in phototherapy.Eur J Dermatol, 2000, 10(8):642-645.
[16] Mayas MD. Photopheresis and autoimmune diseases. Rheum Dis Clin North Am, 2000, 26(1):75-81.
[17] Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol, 2002, 138(1):99-105.
[18] Bingham SJ, Snowden JA, Emery P. Autologous blood stem cell transplantation as therapy for autoimmune diseases. Ann Med, 2000,32(9):615-621.
[19] Furst DE, Tyndall A. Stem cell transplantation in systemic sclerosis:rationale and status report. Isr Med Assoc J, 2000, 2 (12):935-937.
[20] Ellman MH,MeDonald PA, Hayes FA, et al. Etanercept as treatment for diffuse scleroderma:a pilot study [abstract]. Arthritis Rheum,2000,43:S392.
[21] Schachna L, Wigley FM, White B, et al. Lung transplantation in scleroderma:the Johns Hopkins experience [abstract]. Arthritis Rheum,2000,43:S392.
[22] Kubo M, Vensak J, Dauber J, et al. Lung transplantation in patients with scleroderma. J Heart Lung Transplant, 2001, 20 (2):174-175.